Assessment of safety of the major antimalarial drugs

Expert Opinion on Drug Safety

Volumn 6, Issue 5, 2007, Pages 505-521

  Chattopadhyay, Rana ^a   Mahajan, Babita ^a   Kumar, Sanjai ^b  

^a SANARIA INC   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Adverse effects; Antimalarial drug; Plasmodium; Safety

Indexed keywords

AMODIAQUINE; ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; ARTEETHER; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTEMISININ DERIVATIVE; ARTESUNATE; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; CHLOROQUINE PLUS PROGUANIL; CLINDAMYCIN; DIHYDROARTEMISININ; DIHYDROARTEMISININ PLUS PIPERAQUINE; DOXYCYCLINE; FANSIDAR; FOLIC ACID ANTAGONIST; HALOFANTRINE; MEFLOQUINE; PIPERAQUINE; PLACEBO; PRIMAQUINE; PROGUANIL; PYRIMETHAMINE; QUININE; SULFONAMIDE; TETRACYCLINE; UNINDEXED DRUG; MALARIA VACCINE;

ABDOMINAL PAIN; ABORTION; ACUTE BRAIN DISEASE; ACUTE GLOMERULONEPHRITIS; AGRANULOCYTOSIS; ANAPHYLAXIS; ANTIMALARIAL ACTIVITY; ANXIETY DISORDER; ASIAN; ATRIOVENTRICULAR CONDUCTION; BARRETT ESOPHAGUS; BLINDNESS; BLOOD TOXICITY; BLURRED VISION; BRADYCARDIA; BRAIN PSEUDOTUMOR; BRAIN TOXICITY; CARDIOTOXICITY; CAUCASIAN; CHRONIC HEPATITIS; CLINICAL TRIAL; COMA; COMBINATION CHEMOTHERAPY; COMPLETE HEART BLOCK; CONGENITAL MALFORMATION; CONSCIOUSNESS DISORDER; CONVULSION; CROSS RESISTANCE; CYANOSIS; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DIZZINESS; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG OVERDOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHORIA; DYSPNEA; ECG ABNORMALITY; EOSINOPHILIA; ERYTHEMA MULTIFORME; ERYTHRODERMA; ESOPHAGITIS; ETHNIC DIFFERENCE; FACE RASH; FATIGUE; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL TOXICITY; GRANULOMATOUS HEPATITIS; HALLUCINATION; HEADACHE; HEARING IMPAIRMENT; HEART ATRIUM FLUTTER; HEART PALPITATION; HEART VENTRICLE ARRHYTHMIA; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPOGLYCEMIA; HYPOTENSION; INSOMNIA; INSULIN RELEASE; INTRAVASCULAR HEMOLYSIS; JAUNDICE; LEUKOPENIA; LICHEN PLANUS; LICHENOID ERUPTION; LIVER DISEASE; LIVER GRANULOMA; LIVER NECROSIS; LIVER TOXICITY; LOADING DRUG DOSE; LONG TERM CARE; LUNG DISEASE; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MEGALOBLASTIC ANEMIA; MENTAL DISEASE; MILK; MONOTHERAPY; MOOD DISORDER; MOUTH ULCER; MUSCLE ATROPHY; MUSCLE WEAKNESS; MYOCARDITIS; NAUSEA; NEUROLOGIC DISEASE; NEUROMUSCULAR DISEASE; NEUROTOXICITY; NIGHTMARE; NONHUMAN; ODYNOPHAGIA; OTOTOXICITY; PANCREATITIS; PATIENT COMPLIANCE; PHOTOSENSITIVITY; PLASMODIUM; POLYARTHRITIS; PR INTERVAL; PRURITUS; PSORIASIS; PSYCHOSIS; PURPURA; QRS COMPLEX; QT PROLONGATION; RASH; RECOMMENDED DRUG DOSE; RELAPSE; RETINA MACULOPATHY; RETINOPATHY; REVIEW; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; SINUS ARRHYTHMIA; SKIN TOXICITY; SLEEP DISORDER; SPONTANEOUS ABORTION; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TINNITUS; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS; UNSPECIFIED SIDE EFFECT; URTICARIA; VASCULITIS; VERTIGO; VISUAL IMPAIRMENT; VOMITING; WEAKNESS; ANIMAL; DRUG EFFECT; IMMUNOLOGY; METABOLISM; MULTIDRUG RESISTANCE; PHYSIOLOGY;

ANIMALS; ANTIMALARIALS; DRUG RESISTANCE, MULTIPLE; HUMANS; MALARIA; MALARIA VACCINES;

EID: 35348944028     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.6.5.505     Document Type: Review

References (243)

1. SACHS JD: A new global effort to control malaria. Science (2002) 298(5591):122-124.
2. BREMAN JG, EGAN A, KEUSCH GT: The intolerable burden of malaria: a new look at the numbers. Am. J. Trop. Med. Hyg. (2001) 64(1-2 Suppl.):IV-VII.
3. AMINO R, THIBERGE S, SHORTE S, FRISCHKNECHT F, MENARD R: Quantitative imaging of Plasmodium sporozoites in the mammalian host. Crit. Rev. Biol. (2006) 329(11):858-862.
4. FREVERT U, ENGELMANN S, ZOUGBEDE S et al.: Intravital observation of Plasmodium berghei sporozoite infection of the liver. PLoS Biol. (2005) 3(6):E192.
5. WHITE NJ, NOSTEN F, LOOAREESUWAN S et al.: Averting a malaria disaster. Lancet (1999) 353(9168):1965-1967.
6. EDWARDS IR, ARONSON JK: Adverse drug reactions: definitions, diagnosis, and management. Lancet (2000) 356(9237):1255-1259.
7. WHO: The Use of Antimalarial Drugs: Report of a WHO Informal Consultation. (13-17 November 2000) WHO/CDS/RBM/200133. WHO, Geneva, Switzerland (2001).
8. BLOLAND PB, KAZEMBE PN, OLOO AJ et al.: Chloroquine in Africa: critical assessment and recommendations for monitoring and evaluating chloroquine therapy efficacy in sub-Saharan Africa. Trop. Med. Int. Health (1998) 3(7):543-552.
9. GINSBURG H: Should chloroquine be laid to rest? Acta Trop. (2005) 96(1):16-23.
10. MURPHY GS, BASRI H, PURNOMO et al.: Vivax malaria resistant to treatment and prophylaxis with chloroquine. Lancet (1993) 341(8837):96-100.
11. BAIRD JK, BASRI H, PURNOMO et al.: Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am. J. Trop. Med. Hyg. (1991) 44(5):547-552.
12. MYAT PHONE K, MYINT O, MYINT L et al.: Emergence of chloroquine-resistant Plasmodium vivax in Myanmar (Burma). Trans. R. Soc. Trop. Med. Hyg. (1993) 87(6):687.
13. PHILLIPS EJ, KEYSTONE JS, KAIN KC: Failure of combined chloroquine and high-dose primaquine therapy for Plasmodium vivax malaria acquired in Guyana, South America. Clin. Infect. Dis. (1996) 23(5):1171-1173.
14. MNYIKA KS, KIHAMIA CM: Chloroquine-induced pruritus: its impact on chloroquine utilization in malaria control in Dar es Salaam. J. Trop. Med. Hyg. (1991) 94(1):27-31.
15. SOWUNMI A, WALKER O, SALAKO LA: Pruritus and antimalarial drugs in Africans. Lancet (1989) 2(8656):213.
16. WOLF R, RUOCCO V: Triggered psoriasis. Adv. Exp. Med. Biol. (1999) 455:221-225.
17. OLSEN TG: Chloroquine and psoriasis. Ann. Intern. Med. (1981) 94(4 Part 1):546-547.
18. BARRETT PJ, EMMINS PD, CLARKE PD, BRADLEY DJ: Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. BMJ (1996) 313(7056):525-528.
19. CARME B, PEGUET C, NEVEZ G: Compliance with and tolerance of mefloquine and chloroquine + proguanil malaria chemoprophylaxis in French short-term travellers to sub-Saharan Africa. Trop. Med. Int. Health (1997) 2(10):953-956.
20. DURRHEIM DN, GAMMON S, WANER S, BRAACK LE: Antimalarial prophylaxis - use and adverse events in visitors to the Kruger National Park. S. Afr. Med. J. (1999) 89(2):170-175.
21. FOGH S, SCHAPIRA A, BYGBJERG IC et al.: Malaria chemoprophylaxis in travellers to east Africa: a comparative prospective study of chloroquine plus proguanil with chloroquine plus sulfadoxine-pyrimethamine. BMJ (Clin. Res. Ed.) (1988) 296(6625):820-822.
22. HOEBE C, DE MUNTER J, THIJS C: Adverse effects and compliance with mefloquine or proguanil antimalarial chemoprophylaxis. Eur. J. Clin. Pharmacol. (1997) 52(4):269-275.
23. STEFFEN R, FUCHS E, SCHILDKNECHT J et al.: Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet (1993) 341(8856):1299-1303.
24. DRYSDALE SF, PHILLIPS-HOWARD PA, BEHRENS RH: Proguanil, chloroquine, and mouth ulcers. Lancet (1990) 335(8682):164.
25. AVINA-ZUBIETA JA, JOHNSON ES, SUAREZ-ALMAZOR ME, RUSSELL AS: Incidence of myopathy in patients treated with antimalarials. A report of three cases and a review of the literature. Br. J. Rheumatol. (1995) 34(2):166-170.
26. BAMBER MG, ELDER AT, GRAY JA, MINNS RA: Fatal Stevens-Johnson syndrome associated with Fansidar and chloroquine. J. Infect. (1986) 13(1):31-33.
27. BOFFA MJ, CHALMERS RJ: Toxic epidermal necrolysis due to chloroquine phosphate. Br. J. Dermatol. (1994) 131(3):444-445.
28. NAGARATNAM N, CHETIYAWARDANA AD, RAJIYAH S: Aplasia and leukaemia following chloroquine therapy. Postgrad. Med. J. (1978) 54(628):108-112.
29. RYNES RI: Antimalarial drugs in the treatment of rheumatological diseases. Br. J. Rheumatol. (1997) 36(7):799-805.
30. SILMAN A, SHIPLEY M: Ophthalmological monitoring for hydroxychloroquine toxicity: a scientific review of available data. Br. J. Rheumatol. (1997) 36(5):599-601.
31. SHINJO SK, MAIA JUNIOR OO, TIZZIANI VA et al.: Chloroquine-induced bull's eye maculopathy in rheumatoid arthritis: related to disease duration? Clin. Rheumatol. (2007) 26(8):1248-1253.
32. TAYLOR WR, WHITE NJ: Antimalarial drug toxicity: a review. Drug Saf. (2004) 27(1):25-61.
33. PHILLIPS-HOWARD PA, WOOD D: The safety of antimalarial drugs in pregnancy. Drug Saf. (1996) 14(3):131-145.
34. WHO: Advances in malaria chemotherapy. Report of a WHO scientific group (1984). WHO Technical Report Series No. 711.
35. MOTTA M, TINCANI A, FADEN D, ZINZINI E, CHIRICO G: Antimalarial agents in pregnancy. Lancet (2002) 359(9305):524-525.
36. JAEGER A, SAUDER P, KOPFERSCHMITT J, FLESCH F: Clinical features and management of poisoning due to antimalarial drugs. Med. Toxicol. Adverse Drug Exp. (1987) 2(4):242-273.
37. DOBERSTYN EB, TEERAKIARTKAMJORN C, ANDRE RG, PHINTUYOTHIN P, NOEYPATIMANONDH S: Treatment of vivax malaria with sulfadoxine-pyrimethamine and with pyrimethamine alone. Trans. R. Soc. Trop. Med. Hyg. (1979) 73(1):15-17.
38. LOOAREESUWAN S, HARINASUTA T, CHONGSUPHAJAISIDDHI T: Drug resistant malaria, with special reference to Thailand. Southeast Asian J. Trop. Med. Public Health (1992) 23(4):621-634.
39. PETERS PJ, THIGPEN MC, PARISE ME, NEWMAN RD: Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment. Drug Saf. (2007) 30(6):481-501.
40. EKUE JM, PHIRI DE, SHETH UK, MUKUNYANDELA M: A double-blind trial of a fixed combination of mefloquine plus sulfadoxine-pyrimethamine compared with sulfadoxine-pyrimethamine alone in symptomatic falciparum malaria. Bull. World Health Organ. (1987) 65(3):369-373.
41. TJITRA E, SUPRIANTO S, CURRIE BJ et al.: Therapy of uncomplicated falciparum malaria: a randomized trial comparing artesunate plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone in Irian Jaya, Indonesia. Am. J. Trop. Med. Hyg. (2001) 65(4):309-317.
42. MILLER KD, LOBEL HO, SATRIALE RF et al.: Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis. Am. J. Trop. Med. Hyg. (1986) 35(3):451-458.
43. OLSEN VV, LOFT S, CHRISTENSEN KD: Serious reactions during malaria prophylaxis with pyrimethamine-sulfadoxine. Lancet (1982) 2(8305):994.
44. STEFFEN R, SOMAINI B: Severe cutaneous adverse reactions to sulfadoxine-pyrimethamine in Switzerland. Lancet (1986) 1(8481):610.
45. COOPMAN SA, JOHNSON RA, PLATT R, STERN RS: Cutaneous disease and drug reactions in HIV infection. N. Engl. J. Med. (1993) 328(23):1670-1674.
46. LANGTRY JA, HARPER JI, STAUGHTON RC, BARRINGTON P: Erythroderma resembling sezary syndrome after treatment with Fansidar and chloroquine. BMJ (Clin. Res. Ed.) (1986) 292(6528):1107-1108.
47. LAZAR HP, MURPHY RL, PHAIR JP: Fansidar and hepatic granulomas. Ann. Intern. Med. (1985) 102(5):722.
48. WEJSTAL R, LINDBERG J, MALMVALL BE, NORKRANS G: Liver damage associated with fansidar. Lancet (1986) 1(8485):854-855.
49. TONDER M, NORDOY A, ELGJO: Sulfonamide-induced chronic liver disease. Scand. J. Gastroenterol. (1974) 9(1):93-96.
50. ZITELLI BJ, ALEXANDER J, TAYLOR S et al.: Fatal hepatic necrosis due to pyrimethamine-sulfadoxine (Fansidar). Ann. Intern. Med. (1987) 106(3):393-395.
51. SELBY CD, LADUSANS EJ, SMITH PG: Fatal multisystemic toxicity associated with prophylaxis with pyrimethamine and sulfadoxine (Fansidar). BMJ (Clin. Res. Ed.) (1985) 290(6462):113-114.
52. SVANBOM M, ROMBO L, GUSTAFSSON L: Unusual pulmonary reaction during short term prophylaxis with pyrimethamine-sulfadoxine (Fansidar). BMJ (Clin. Res. Ed.) (1984) 288(6434):1876.
53. MCCORMACK D, MORGAN WK: Fansidar hypersensitivity pneumonitis. Br. J. Dis. Chest (1987) 81(2):194-196.
54. HITCHINGS GH: Daraprim as an antagonist of folic and folinic acids. Trans. R. Soc. Trop. Med. Hyg. (1952) 46(5):467-473; discussion 498-508.
55. CHUTE JP, DECKER CF, COTELINGAM J: Severe megaloblastic anemia complicating pyrimethamine therapy. Ann. Intern. Med. (1995) 122(11):884-885.
56. WICKRAMASINGHE SN, LITWINCZUK RA: Effects of low concentrations of pyrimethamine on human bone marrow cells in vitro: possible implications for malaria prophylaxis. J. Trop. Med. Hyg. (1981) 84(6):233-238.
57. SHULMAN CE, DORMAN EK, CUTTS F et al.: Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial. Lancet (1999) 353(9153):632-636.
58. PARISE ME, AYISI JG, NAHLEN BL et al.: Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am. J. Trop. Med. Hyg. (1998) 59(5):813-822.
59. VERHOEFF FH, BRABIN BJ, CHIMSUKU L et al.: An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi. Ann. Trop. Med. Parasitol. (1998) 92(2):141-150.
60. SCHULTZ LJ, STEKETEE RW, MACHESO A et al.: The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. Am. J. Trop. Med. Hyg. (1994) 51(5):515-522.
61. NO AUTHORS LISTED: Pyrimethamine combinations in pregnancy. Lancet (1983) 2(8357):1005-1007.
62. NOTARIANNI LJ: Plasma protein binding of drugs in pregnancy and in neonates. Clin. Pharmacokinet. (1990) 18(1):20-36.
63. HERNANDEZ-DIAZ S, WERLER MM, WALKER AM, MITCHELL AA: Folic acid antagonists during pregnancy and the risk of birth defects. N. Engl. J. Med. (2000) 343(22):1608-1614.
64. EDSTEIN MD, VEENENDAAL JR, NEWMAN K, HYSLOP R: Excretion of chloroquine, dapsone and pyrimethamine in human milk. Br. J. Clin. Pharmacol. (1986) 22(6):733-735.
65. NOSTEN F, VAN VUGT M, PRICE R et al.: Effects of arresunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet (2000) 356(9226):297-302.
66. CERUTTI C Jr, DURLACHER RR, DE ALENCAR FE, SEGURADO AA, PANG LW: In vivo efficacy of mefloquine for the treatment of falciparum malaria in Brazil. J. Infect. Dis. (1999) 180(6):2077-2080.
67. LOBEL HO, VARMA JK, MIANI M et al.: Monitoring for mefloquine-resistant Plasmodium falciparum in Africa: implications for travelers' health. Am. J. Trop. Med. Hyg. (1998) 59(1): 129-132.
68. TER KUILE FO, NOSTEN F, LUXEMBURGER C et al.: Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients. Bull. World Health Organ. (1995) 73(5):631-642.
69. CENTRES FOR DISEASE CONTROL AND PREVENTION: Health Information for International Travel 2005-2006. Chapter 4 (2005).
70. EVANS MR, DAY JH, BEHRENS RH: Prevention and treatment of malaria in UK travellers. Hosp. Med. (2000) 61(3):162-166.
71. NOSTEN F, PRICE RN: New antimalarials. A risk-benefit analysis. Drug Saf. (1995) 12(4):264-273.
72. KOFI EKUE JM, ULRICH AM, RWABWOGO-ATENYI J, SHETH UK: A double-blind compararive clinical trial of mefloquine and chloroquine in symptomatic falciparum malaria. Bull. World Health Organ. (1983) 61(4):713-718.
73. TER KUILE FO, DOLAN G, NOSTEN F et al.: Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet(1993) 341(8852): 1044-1049.
74. LOOAREESUWAN S, WILAIRATANA P, CHOKEJINDACHAI W et al.: A randomized, double-blind, comparative trial of a new oral combination of artemether and benflumetol (CGP 56697) with mefloquine in the treatment of acute Plasmodium falciparum malaria in Thailand. Am. J. Trop. Med. Hyg. (1999) 60(2):238-243.
75. PHILLIPS-HOWARD PA, TER KUILE FO: CNS adverse events associated with antimalarial agents. Factor fiction? Drug Saf. (1995) 12(6):370-383.
76. SCHLAGENHAUF P: Mefloquine for malaria chemoprophylaxis 1992-1998: a review. J. Travel. Med. (1999) 6(2):122-133.
77. HAVALDAR PV, MOGALE KD: Mefloquine-induced psychosis. Pediatr. Infect. Dis. J. (2000) 19(2):166-167.
78. POTASMAN I, BENY A, SELIGMANN H: Neuropsychiatric problems in 2,500 long-term young travelers to the tropics. J. Travel Med. (2000) 7(1):5-9.
79. WEINKE T, TRAUTMANN M, HELD T et al.: Neuropsychiatric side effects after the use of mefloquine. Am. J. Trop. Med. Hyg. (1991) 45(1):86-91.
80. SOWUNMI A, SALAKO LA, ODUOLA AM et al.: Neuropsychiatric side effects of mefloquine in Africans. Trans. R. Soc. Trop. Med. Hyg. (1993) 87(4):462-463.
81. WHO: Review of central nervous system adverse events related to the antimalarial drug, mefloquine (1985-1990). WHO, Geneva, Switzerland (1991).
82. AARNOUDSE AL, VAN SCHAIK RH, DIELEMAN J et al.: MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. Clin. Pharmacol. Ther. (2006) 80(4):367-374.
83. BEM JL, KERR L, STUERCHLER D: Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. J. Trop. Med. Hyg. (1992) 95(3):167-179.
84. NOSTEN F, TER KUILE FO, LUXEMBURGER C et al.: Cardiac effects of antimalarial treatment with halofantrine. Lancet (1993) 341(8852):1054-1056.
85. KARBWANG J, NA-BANGCHANG K, THANAVIBUL A et al.: Comparison of oral artesunate and quinine plus tetracycline in acute uncomplicated falciparum malaria. Bull. World Health Organ. (1994) 72(2):233-238.
86. HARINASUTA T, BUNNAG D, WERNSDORFER WH: A Phase II clinical trial of mefloquine in patients with chloroquine-resistant falciparum malaria in Thailand. Bull. World Health Organ. (1983) 61(2):299-305.
87. FONTEYNE W, BAUWENS A, JORDAENS L: Atrial flutter with 1:1 conduction after administration of the antimalarial drug mefloquine. Clin. Cardiol. (1996) 19(12):967-968.
88. RICHTER J, BURBACH G, HELLGREN U, DENGLER A, BIENZLE U: Aberrant atrioventricular conduction triggered by antimalarial prophylaxis with mefloquine. Lancet (1997) 349(9045):101-102.
89. DANIS M, NOZAIS JP, PARIS L et al.: Blackwater fever after ingestion of mefloquine: three cases. Presse Med. (1993) 22:80.
90. VAN DEN ENDE J, COPPENS G, VERSTRAETEN T et al.: Recurrence of blackwater fever: triggering of relapses by different antimalarials. Trop. Med. Int. Health (1998) 3(8):632-639.
91. MCBRIDE SR, LAWRENCE CM, PAPE SA, REID CA: Fatal toxic epidermal necrolysis associated with mefloquine antimalarial prophylaxis. Lancet (1997) 349(9045):101.
92. VAN DEN ENDEN E, VAN GOMPEL A, COLEBUNDERS R, VAN DEN ENDE J: Mefloquine-induced Stevens-Johnson syndrome. Lancet (1991) 337(8742):683.
93. SHLIM DR: Severe facial rash associated with mefloquine. JAMA (1991) 266(18):2560.
94. SCERRI L, PACE JL: Mefloquine-associated cutaneous vasculitis. Int. J. Dermatol. (1993) 32(7):517-518.
95. STEKETEE RW, WIRIMA JJ, SLUTSKER L et al.: Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. Am. J. Trop. Med. Hyg. (1996) 55(1 Suppl.):50-56.
96. STEKETEE RW, WIRIMA JJ, SLUTSKER L et al.: Malaria parasite infection during pregnancy and at delivery in mother, placenta, and newborn: efficacy of chloroquine and mefloquine in rural Malawi. Am. J. Trop. Med. Hyg. (1996) 55(1 Suppl.):24-32.
97. NOSTEN F, TER KUILE F, MAELANKIRI L et al.: Mefloquine prophylaxis prevents malaria during pregnancy: a double-blind, placebo-controlled study. J. Infect. Dis. (1994) 169(3):595-603.
98. NOSTEN F, VINCENTI M, SIMPSON J et al.: The effects of mefloquine treatment in pregnancy. Clin. Infect. Dis. (1999) 28(4):808-815.
99. VANHAUWERE B, MARADIT H, KERR L: Post-marketing surveillance of prophylactic mefloquine (Lariam) use in pregnancy. Am. J. Trop. Med. Hyg. (1998) 58(1):17-21.
100. PHILLIPS-HOWARD PA, STEFFEN R, KERR L et al.: Safety of mefloquine and other antimalarial agents in the first trimester of pregnancy. J. Travel. Med. (1998) 5(3):121-126.
101. ADAM I, ALI DA, ALWASEILA A, KHEIR MM, ELBASHIR MI: Mefloquine in the treatment of falciparum malaria during pregnancy in Eastern Sudan. Saudi Med. J. (2004) 25(10):1400-1402.
102. EDSTEIN MD, VEENENDAAL JR, HYSLOP R: Excretion of mefloquine in human breast milk. Chemotherapy (1988) 34(3):165-169.
103. KARBWANG J, WHITE NJ: Clinical pharmacokinetics of mefloquine. Clin. Pharmacokinet. (1990) 19(4):264-279.
104. WHO: Guidelines for the Treatment of Malaria (2006). (WHO/HTM/MAL/ (2006). 1108) WHO.
105. WHITE NJ, LOOAREESUWAN S, WARRELL DA et al.: Quinine loading dose in cerebral malaria. Am. J. Trop. Med. Hyg. (1983) 52(1):1-5.
106. MILLER RS, WONGSRICHANALAI C, BUATHONG N et al.: Effective treatment of uncomplicated Plasmodium falciparum malaria with azithromycin-quinine combinations: a randomized, dose-ranging study. Am. J. Trop. Med. Hyg. (2006) 74(3):401-406.
107. VIEIRA JL, MIDIO AF: Drug monitoring of quinine in men with nonsevere falciparum malaria: study in the Amazon region of Brazil. The Drug Monit. (2001) 23(6):612-615.
108. CLAESSEN FA, VAN BOXTEL CJ, PERENBOOM RM et al.: Quinine pharmacokinetics: ototoxic and cardiotoxic effects in healthy Caucasian subjects and in patients with falciparum malaria. Trop. Med. Int. Health (1998) 3(6):482-489.
109. OKITOLONDA W, DELACOLLETTE C, MALENGREAU M, HENQUIN JC: High incidence of hypoglycaemia in African patients treated with intravenous quinine for severe malaria. BMJ (Clin. Res. Ed.) (1987) 295(6600):716-718.
110. WHITE NJ, WARRELL DA, CHANTHAVANICH P et al.: Severe hypoglycemia and hyperinsulinemia in falciparum malaria. N. Engl. J. Med. (1983) 309(2):61-66.
111. BONINGTON A, DAVIDSON RN, WINSTANLEY PA, PASVOL G: Fatal quinine cardiotoxicity in the treatment of falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. (1996) 90(3):305-307.
112. A meta-analysis using individual patient data of trials comparing artemether with quinine in the treatment of severe falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. (2001) 95(6):637-650.
113. SUPANARANOND W, DAVIS TM, PUKRITTAYAKAMEE S, NAGACHINTA B, WHITE NJ: Abnormal circulatory control in falciparum malaria: the effects of antimalarial drugs. Eur. J. Clin. Pharmacol. (1993) 44(4):325-329.
114. BOTTIGER LE, FURHOFF AK, HOLMBERG L: Drug-induced blood dyscrasias. A ten-year material from the Swedish adverse drug reaction committee. Acta Med. Scand. (1979) 205(6):457-461.
115. DANIELSON DA, DOUGLAS SW III, HERZOG P, JICK H, PORTER JB: Drug-induced blood disorders. JAMA (1984) 252(23):3257-3260.
116. FREIMAN JP: Fatal quinine-induced thrombocytopenia. Ann. Intern. Med. (1990) 112(4):308-309.
117. MAN-SON-HING M, WELLS G: Meta-analysis of efficacy of quinine for treatment of nocturnal leg cramps in elderly people. BMJ (1995) 310(6971):13-17.
118. GOTTSCHALL JL, NEAHRING B, MCFARLAND JG et al.: Quinine-induced immune thrombocytopenia with hemolytic uremic syndrome: clinical and serological findings in nine patients and review of literature. Am. J. Hematol. (1994) 47(4):283-289.
119. SPEARING RL, HICKTON CM, SIZELAND P, HANNAH A, BAILEY RR: Quinine-induced disseminated intravascular coagulation. Lancet (1990) 336(8730):1535-1537.
120. BARR E, DOUGLAS JF, HILL CM: Recurrent acute hypersensitivity to quinine. BMJ (1990) 301(6747):323.
121. MAGUIRE RB, STRONCEK DF, CAMPBELL AC: Recurrent pancytopenia, coagulopathy, and renal failure associated with multiple quinine-dependent antibodies. Ann. Intern. Med. (1993) 119(3):215-217.
122. LJUNGGREN B, SJOVALL P: Systemic quinine photosensitivity. Arch. Dermatol. (1986) 122(8):909-911.
123. GUZZO C, KAIDBEY K: Persistent light reactivity from systemic quinine. Photodermatol. Photoimmunol. Photomed. (1990) 7(4):166-168.
124. PRICE EJ, BEVAN JS, REES A: Quinine-induced cutaneous vasculitis. Br. J. Clin. Pract. (1992) 46(2):138-139.
125. MEYRICK THOMAS RH, MUNRO DD: Lichen planus in a photosensitive distribution due to quinine. Clin. Exp. Dermatol. (1986) 11(1):97-101.
126. HOU M, HORNEY E, STOCKELBERG D et al.: Multiple quinine-dependent antibodies in a patient with episodic thrombocytopenia, neutropenia, lymphocytopenia, and granulomatous hepatitis. Blood (1997) 90(12):4806-4811.
127. PUNUKOLLU RC, KUMAR S, MULLEN KD: Quinine hepatotoxicity. An underrecognized or rare phenomenon? Arch. Intern. Med. (1990) 150(5):1112-1113.
128. NOSTEN F, MCGREADY R, D'ALESSANDRO U: Antimalarial drugs in pregnancy: a review. Curr. Drug Saf. (2006) 1:1-15.
129. BOLAND ME, ROPER SM, HENRY JA: Complications of quinine poisoning. Lancet (1985) 1(8425):384-385.
130. DYSON EH, PROUDFOOT AT, PRESCOTT LF, HEYWORTH R: Death and blindness due to overdose of quinine. BMJ (Clin. Res. Ed.) (1985) 291(6487):31-33.
131. BATEMAN DN, BLAIN PG, WOODHOUSE KW et al.: Pharmacokinetics and clinical toxicity of quinine overdosage: lack of efficacy of techniques intended to enhance elimination. Q. J. Med. (1985) 54(214):125-131.
132. LOOAREESUWAN S, PHILLIPS RE, WHITE NJ et al.: Quinine and severe falciparum malaria in late pregnancy. Lancet (1985) 2(8445):4-8.
133. MCGREADY R, NOSTEN F: The Thai-Burmese border: drug studies of Plasmodium faciparum in pregnancy. Ann. Trop. Med. Parasitol. (1999) 93(Suppl. 1):S19-S23.
134. MCGREADY R, THWAI KL, CHO T et al.: The effects of quinine and chloroquine antimalarial treatments in the first trimester of pregnancy. Trans. R. Soc. Trop. Med. Hyg. (2002) 96(2):180-184.
135. NO AUTHORS LISTED: Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans. R. Soc. Trop. Med. Hyg. (2000) 94(Suppl. 1):S1-S90.
136. PHILLIPS RE, LOOAREESUWAN S, WHITE NJ et al.: Quinine pharmacokinetics and toxicity in pregnant and lactating women with falciparum malaria. Br. J. Clin. Pharmacol. (1986) 21(6):677-683.
137. FRYAUFF DJ, BAIRD JK, BASRI H et al.: Halofantrine and primaquine for radical cure of malaria in Irian Jaya, Indonesia. Ann. Trop. Med. Parasitol. (1997) 91(1):7-16.
138. BAIRD JK, BASRI H, SUBIANTO B et al.: Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J. Infect. Dis. (1995) 171(6):1678-1682.
139. BOUCHAUD O, BASCO LK, GILLOTIN C et al.: Clinical efficacy and pharmacokinetics of micronized halofantrine for the treatment of acute uncomplicated falciparum malaria in nonimmune patients. Am. J. Trop. Med. Hyg. (1994) 51(2):204-213.
140. BRASSEUR P, BITSINDOU P, MOYOU RS et al.: Fast emergence of Plasmodium falciparum resistance to halofantrine. Lancet (1993) 341(8849):901-902.
141. KARBWANG J, NA BANGCHANG K: Clinical pharmacokinetics of halofantrine. Clin. Pharmacokinet. (1994) 27(2):104-119.
142. MOJON M, WALLON M, GRAVEY A et al.: Intravascular haemolysis following halofantrine intake. Trans. R. Soc. Trop. Med. Hyg. (1994) 88(1):91.
143. GILLESPIE SH, MSAKI EP, RAMSAY A, NGOWI FI, FOX R: A new micronized formulation of halofantrine hydrochloride in the treatment of acute Plasmodium falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. (1993) 87(4):467-469.
144. VACHON F, FAJAC I, GACHOT B, COULAUD JP, CHARMOT G: Halofantrine and acute intravascular haemolysis. Lancet (1992) 340(8824):909-910.
145. SALAKO LA, SOWUNMI A, WALKER O: Evaluation of the clinical efficacy and safety of halofantrine in falciparum malaria in Ibadan, Nigeria. Trans. R. Soc. Trop. Med. Hyg. (1990) 84(5):644-647.
146. COULAUD JP, LE BRAS J, MATHERON S et al.: Treatment of imported cases of falciparum malaria in France with halofantrine. Trans. R. Soc. Trop. Med. Hyg. (1986) 80(4):615-617.
147. MALVY D, RECEVEUR MC, OZON P et al.: Fatal cardiac incident after use of halofantrine. J. Travel. Med. (2000) 7(4):215-216.
148. SOWUNMI A, FALADE CO, ODUOLA AM et al.: Cardiac effects of halofantrine in children suffering from acute uncomplicated falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. (1998) 92(4):446-448.
149. GUNDERSEN SG, ROSTRUP M, VON DER LIPPE E et al.: Halofantrine-associated ventricular fibrillation in a young woman with no predisposing QTc prolongation. Scand. J. Infect. Dis. (1997) 29(2):207-208.
150. HUMBERSTONE AJ, COWMAN AF, HORTON J, CHARMAN WN; Effect of altered serum lipid concentrations on the IC50 of halofantrine against Plasmodium falciparum. J. Pharm. Sci. (1998) 87(2):256-258.
151. SHANKS GD, WATT G, EDSTEIN MD et al.: Halofantrine given with food for falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. (1992) 86(3):233-234.
152. MILTON KA, EDWARDS G, WARD SA, ORME ML, BRECKENRIDGE AM: Pharmacokinetics of halofantrine in man: effects of food and dose size. Br. J. Clin. Pharmacol. (1989) 28(1):71-77.
153. MONLUN E, LE METAYER P, SZWANDT S et al.: Cardiac complications of halofantrine: a prospective study of 20 patients. Trans. R. Soc. Trop. Med. Hyg. (1995) 89(4):430-433.
154. ARNOLD J, ALVING AS, HOCKWALD RS et al.: The effect of continuous and intermittent primaquine therapy on the relapse rate of Chesson strain vivax malaria. J. Lab. Clin. Med. (1954) 44(3):429-438.
155. PUKRITTAYAKAMEE S, VANIJANONTA S, CHANTRA A, CLEMENS R, WHITE NJ: Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. J. Infect. Dis. (1994) 169(4):932-935.
156. WILAIRATANA P, SILACHAMROON U, KRUDSOOD S et al.: Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand. Am. J. Trop. Med. Hyg. (1999) 61(6):973-977.
157. FRYAUFF DJ, BAIRD JK, BASRI H et al.: Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet (1995) 346 (8984):1190-1193.
158. BAIRD JK, FRYAUFF DJ, BASRI H et al.: Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia. Am. J. Trop. Med. Hyg. (1995) 52(6):479-484.
159. WEISS WR, OLOO AJ, JOHNSON A, KOECH D, HOFFMAN SL: Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. J. Infect. Dig. (1995) 171(6):1569-1575.
160. GOGTAY NJ, DESAI S, KAMTEKAR KD et al.: Efficacies of 5- and 14-day primaquine regimens in the prevention of relapses in Plasmodium vivax infections. Ann. Trop. Med. Parasitol. (1999) 93(8):809-812.
161. SMOAK BL, DEFRAITES RF, MAGILL AJ, KAIN KC, WELLDE BT: Plasmodium vivax infections in US Army troops: failure of primaquine to prevent relapse in studies from Somalia. Am. J. Trop. Med. Hyg. (1997) 56(2):231-234.
162. DOHERTY JF, DAY JH, WARHURST DC, CHIODINI PL: Treatment of Plasmodium vivax malaria - time for a change? Trans. R. Soc. Trop. Med. Hyg. (1997) 91(1):76.
163. BUNNAG D, KARBWANG J, THANAVIBUL A et al.: High dose of primaquine in primaquine resistant vivax malaria. Trans. R. Soc. Trop. Med. Hyg. (1994) 88(2):218-219.
164. CLAYMAN CB, ARNOLD J, HOCKWALD RS et al.: Toxicity of primaquine in Caucasians. J. Am. Med. Assoc. (1952) 149(17):1563-1568.
165. HANSEN JE, CLEVE EA, PRUITT FW: Relapse of vivax malaria treated with primaquine and report of one case of cyanosis (methemoglobinemia) due to primaquine. Am. J. Med. Sci. (1954) 227(1):9-12.
166. SIETSMA A, NAUGHTON MA, HARLEY JD: Methaemoglobin levels in soldiers receiving antimalarial drugs. Med. J. Aust. (1971) 1(9):473-475.
167. BRENNECKE FE AA, ARNOLD J et al.: A preliminary report on the effect of certain 8-aminoquinolines in the treatment of rheumatoid arthritis. J. Lab. Clin. Med. (1951) 38:795-796.
168. CARSON PE, HOHL R, NORA MV et al.: Toxicology of the 8-aminoquinolines and genetic factors associated with their toxicity in man. Bull. World Health Organ. (1981) 59(3):427-437.
169. KHOO KK: The treatment of malaria in glucose-6-phosphate dehydrogenase deficient patients in Sabah. Ann. Trop. Med. Parasitol. (1981) 75(6):591-595.
170. SALVIDIO E, PANNACCIULLI I, TIZIANELLO A, AJMAR F: Nature of hemolytic crises and the fate of G6PD deficient, drug-damaged erythrocytes in Sardinians. N. Engl. J. Med. (1967) 276(24):1339-1344.
171. HOCKWALD RS, ARNOLD J, CLAYMAN CB, ALVING AS: Toxicity of primaquine in Negroes. J. Am. Med. Assoc. (1952) 149(17):1568-1570.
172. LOOAREESUWAN S, VIRAVAN C, WEBSTER HK et al.: Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am. J. Trop. Med. Hyg. (1996) 54(1):62-66.
173. LOOAREESUWAN S, WILAIRATANA P, CHALERMARUT K et al.: Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand. Am. J. Trop. Med. Hyg. (1999) 60(4):526-532.
174. RADLOFF PD, PHILIPPS J, NKEYI M, HUTCHINSON D, KREMSNER PG: Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet (1996) 347(9014):1511-1514.
175. ROLAN PE, MERCER AJ, WEATHERLEY BC et al.: Examination of some factors responsible for a food-induced increase in absorption of atovaquone. Br. J. Clin. Pharmacol. (1994) 37(1):13-20.
176. HOGH B, CLARKE PD, CAMUS D et al.: Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone international study team. Lancet (2000) 356(9245):1888-1894.
177. SUKWA TY, MULENGA M, CHISDAKA N, ROSKELL NS, SCOTT TR: A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. Am. J. Trop. Med. Hyg. (1999) 60(4):521-525.
178. SHANKS GD, GORDON DM, KLOTZ FW et al.: Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. Clin. Infect. Dig. (1998) 27(3):494-499.
179. LOOAREESUWAN S, CHULAY JD, CANFIELD CJ, HUTCHINSON DB: Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone clinical trials study group. Am. J. Trop. Med. Hyg. (1999) 60(4):533-541.
180. ADJUIK M, BABIKER A, GARNER P et al.: Artesunate combinations for treatment of malaria: meta-analysis. Lancet (2004) 363(9402):9-17.
181. PRICE RN: Artemisinin drugs: novel antimalarial agents. Expert Opin. Investig. Drugs (2000) 9(8):1815-1827.
182. PARK BK, O'NEILL PM, MAGGS JL, PIRMOHAMED M: Safety assessment of peroxide antimalarials: clinical and chemical perspectives. Br. J. Clin. Pharmacol. (1998) 46(6):521-529.
183. KISSINGER E, HIEN TT, HUNG NT et al.: Clinical and neurophysiological study of the effects of multiple doses of artemisinin on brain-stem function in Vietnamese patients. Am. J. Trop. Med. Hyg. (2000) 63(1-2):48-55.
184. PRICE R, VAN VUGT M, PHAIPUN L et al.: Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am. J. Trop. Med. Hyg. (1999) 60(4):547-555.
185. VAN VUGT M, ANGUS BJ, PRICE RN et al.: A case-control auditory evaluation of patients treated with artemisinin derivatives for multidrug-resistant Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. (2000) 62(1):65-69.
186. TOOVEY S, JAMIESON A: Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans. R. Soc. Trop. Med. Hyg. (2004) 98(5):261-267, discussion 268-269.
187. TOOVEY S: Comment on: no hearing loss associated with the use of artemether-lumefantrine to treat experimental human malaria. Trans. R. Soc. Trop. Med. Hyg. (2007) 101(3):314-315; author reply 315-316.
188. TOOVEY S: A case-control auditory evaluation of patients treated with artemether-lumefantrine. Am. J. Trop. Med. Hyg. (2006) 74(6):939-940; author reply 940.
189. MCCALL MB, BEYNON AJ, MYLANUS EA, VAN DER VEN AJ, SAUERWEIN RW: No hearing loss associated with the use of artemether-lumefantrine to treat experimental human malaria. Trans. R. Soc. Trop. Med. Hyg. (2006) 100(12):1098-1104.
190. WANG TY: Follow-up observation on the therapeutic effects and remote reactions of artemisinin (Qinghaosu) and artemether in treating malaria in pregnant woman. J. Tradit. Chin. Med. (1989) 9(1):28-30.
191. MCGREADY R, CHO T, CHO JJ et al.: Artemisinin derivatives in the treatment of falciparum malaria in pregnancy. Trans. R. Soc. Trop. Med. Hyg. (1998) 92(4):430-433.
192. MCGREADY R, BROCKMAN A, CHO T et al.: Randomized comparison of mefloquine-artesunate versus quinine in the treatment of multidrug-resistant falciparum malaria in pregnancy. Trans. R. Soc. Trop. Med. Hyg. (2000) 94(6):689-693.
193. MCGREADY R, CHO T, KEO NK et al.: Artemisinin antimalarials in pregnancy: a prospective treatment, study of 539 episodes of multidrug-resistant Plasmodium falciparum. Clin. Infect. Dig. (2001) 33(12):2009-2016.
194. DEEN JL, VON SEIDLEIN L, PINDER M, WALRAVEN GE, GREENWOOD BM: The safety of the combination artesunate and pyrimethamine-sulfadoxine given during pregnancy. Trans. R. Soc. Trop. Med. Hyg. (2001) 95(4):424-428.
195. DELLICOUR S, HALL S, CHANDRAMOHAN D, GREENWOOD B: The safety of artemisinins during pregnancy: a pressing question. Malar. J. (2007) 6:15.
196. ASHLEY EA, WHITE NJ: Artemisinin-based combinations. Curr. Opin. Infect. Dig. (2005) 18(6):531-536.
197. MUTABINGWA TK: Artemisinin-based combination therapies (ACTs): best hope for malaria treatment but inaccessible to the needy! Acta Trop. (2005) 95(3):305-315.
198. DUFFY PE, MUTABINGWA TK: Artemisinin combination therapies. Lancet (2006) 367(9528):2037-2039.
199. WHO: Antimalaria drug combination therapy: report of a WHO technical consultation (2001). WHO/CDS/RBM/2001.35.
200. HATZ C, ABDULLA S, MULL R et al.: Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to treat acute falciparum malaria in Tanzanian children aged 1 - 5 years. Trop. Med. Int. Health (1998) 3(6):498-504.
201. VON SEIDLEIN L, BOJANG K, JONES P et al.: A randomized controlled trial of artemether/benflumetol, a new antimalarial and pyrimethamine/ sulfadoxine in the treatment of uncomplicated falciparum malaria in African children. Am. J. Trop. Med. Hyg. (1998) 58(5):638-644.
202. VON SEIDLEIN L, JAFFAR S, PINDER M et al.: Treatment of African children with uncomplicated falciparum malaria with a new antimalarial drug, CGP 56697. J. Infect. Dig. (1997) 176(4):1113-1116.
203. KOKWARO G, MWAI L, NZILA A: Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. Expert Opin. Pharmacother. (2007) 8(1):75-94.
204. HUTAGALUNG R, HTOO H, NWEE P et al.: A case-control auditory evaluation of patients treated with artemether-lumefantrine. Am. J. Trop. Med. Hyg. (2006) 74(2):211-214.
205. MAYXAY M, THONGPRASEUTH V, KHANTHAVONG M et al.: An open, randomized comparison of artesunate plus mefloquine vs. dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Lao People's Democratic Republic (Laos). Trop. Med. Int. Health (2006) 11(8):1157-1165.
206. BHATT KM, SAMIA BM, BHATT SM, WASUNNA KM: Efficacy and safety of an artesunate/mefloquine combination, (artequin) in the treatment of uncomplicated P. falciparum malaria in Kenya. East Afr. Med. J. (2006) 83(5):236-242.
207. HASUGIAN AR, PURBA HL, KENANGALEM E et al.: Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin. Infect. Dig. (2007) 44(8): 1067-1074.
208. ADAM I, ALI DM, ABDALLA MA: Artesunate plus sulfadoxine-pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria during pregnancy in eastern Sudan. Trans. R. Soc. Trop. Med. Hyg. (2006) 100(7):632-635.
209. OBONYO CO, OCHIENG F, TAYLOR WR et al.: Artesunate plus sulfadoxine-pyrimethamine for uncomplicated malaria in Kenyan children: a randomized, double-blind, placebo-controlled trial. Trans. R. Soc. Trop. Med. Hyg. (2003) 97(5):585-591.
210. PRIOTTO G, KABAKYENGA J, PINOGES L et al.: Artesunate and sulfadoxine-pyrimethamine combinations for the treatment of uncomplicated Plasmodium falciparum malaria in Uganda: a randomized, double-blind, placebo-controlled trial. Trans. R. Soc. Trop. Med. Hyg. (2003) 97(3):325-330.
211. COHLAN SQ: Teratogenic agents and congenital malformations. J. Pediatr. (1963) 63:650-659.
212. MANSON JD: Tetracyclines and the teeth. Lancet (1966) 1(7446):1104.
213. SCHIFFER MA: Fatty liver associated with administration of tetracycline in pregnant and nonpregnant women. Am. J. Obstet. Gynecol. (1966) 96(3):326-332.
214. SCHWARTZ E, REGEV-YOCHAY G: Primaquine as prophylaxis for malaria for nonimmune travelers: a comparison with mefloquine and doxycycline, Clin. Infect. Dig. (1999) 29(6):1502-1506.
215. ANDERSEN SL, OLOO AJ, GORDON DM et al.: Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. Clin. Infect. Dig. (1998) 26(1):146-150.
216. SHANKS GD, ROESSLER P, EDSTEIN MD, RIECKMANN KH: Doxycycline for malaria prophylaxis in Australian soldiers deployed to United Nations missions in Somalia and Cambodia. Mil. Med. (1995) 160(9):443-445.
217. SCHLAGENHAUF P, TSCHOPP A, JOHNSON R et al.: Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. BMJ (2003) 327(7423):1078.
218. KITCHENER SJ, NASVELD PE, GREGORY RM, EDSTEIN MD: Mefloquine and doxycycline malaria prophylaxis in Australian soldiers in East Timor. Med. J. Aust. (2005) 182(4):168-171.
219. DEHAAN RM, METZLER CM, SCHELLENBERG D, VANDENBOSCH WD, MASSON EL: Pharmacokinetic studies of clindamycin hydrochloride in humans. Int. J. Clin. Pharmacol. (1972) 6(2):105-119.
220. LELL B, KREMSNER PG: Clindamycin as an antimalarial drug: review of clinical trials. Antimicrob. Agents Chemother. (2002) 46(8):2315-2320.
221. KREMSNER PG, WILDLING E, JENNE L, GRANINGER W, BIENZLE U: Comparison of micronized halofantrine with chloroquine-antibiotic combinations for treating Plasmodium falciparum malaria in adults from Gabon. Am. J. Trop. Med. Hyg. (1994) 50(6):790-795.
222. KREMSNER PG, WINKLER S, BRANDTS C et al.: Clindamycin in combination with chloroquine or quinine is an effective therapy for uncomplicated Plasmodium falciparum malaria in children from Gabon. J. Infect. Dig. (1994) 169(2):467-470.
223. KREMSNER PG, RADLOFF P, METZGER W et al: Quinine plus clindamycin improves chemotherapy of severe malaria in children. Antimicrob. Agents Chemother. (1995) 39(7):1603-1605.
224. VAILLANT M, MILLET P, LUTYA et al.: Therapeutic efficacy of clindamycin in combination with quinine for treating uncomplicated malaria in a village dispensary in Gabon. Trop. Med. Int. Health (1997) 2(9):917-919.
225. PUKRITTAYAKAMEE S, CHANTRA A, VANIJANONTA S et al.: Therapeutic responses to quinine and clindamycin in multidrug-resistant falciparum malaria. Antimicrob. Agents Chemother. (2000) 44(9):2395-2398.
226. STEER HW: The pseudomembranous colitis associated with clindamycin therapy - a viral colitis. Gut (1975) 16(9):695-706.
227. SMART RF, RAMSDEN DA, GEAR MW, NICOL A, LENNOX WM: Severe pseudomembranous colitis after lincomycin and clindamycin. Br. J. Surg. (1976) 63(1):25-29.
228. MAHBOOB A, HAROON TS: Drugs causing fixed eruptions: a study of 450 cases. Int. J. Dermatol. (1998) 37(11):833-838.
229. KIM P, YOUNAN N, CORONEO MT: Hypersensitivity reaction to intravitreal clindamycin therapy. Clin. Exp. Ophthalmol. (2002) 30(2):147-148.
230. CHIOU CS, LIN SM, LIN SP et al.: Clindamycin-induced anaphylactic shock during general anesthesia. J. Chin. Med. Assoc. (2006) 69(11):549-551.
231. HALL CM, MILLIGAN DW, BERRINGTON J: Probable adverse reaction to a pharmaceutical excipient. Arch. Dig. Child Fetal Neonatal Ed. (2004) 89(2):F184.
232. JOMAA H, WIESNER J, SANDERBRAND S et al.: Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science (1999) 285(5433):1573-1576.
233. LELL B, RUANGWEERAYUT R, WIESNER J et al.: Fosmidomycin, a novel chemotherapeutic agent for malaria. Antimicrob. Agents Chemother. (2003) 47(2):735-738.
234. MISSINOU MA, BORRMANN S, SCHINDLER A et al.: Fosmidomycin for malaria. Lancet (2002) 360(9349):1941-1942.
235. WIESNER J, BORRMANN S, JOMAA H: Fosmidomycin for the treatment of malaria. Parasitol. Res. (2003) 90(Suppl. 2):S71-S76.
236. BORRMANN S, ISSIFOU S, ESSER G et al.: Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria. J. Infect. Dig. (2004) 190(9):1534-1540.
237. OYAKHIROME S, ISSIFOU S, PONGRATZ P et al.: Randomized controlled trial of fosmidomycin-clindamycin versus sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria. Antimicrob. Agents Chemother. (2007) 51(5):1869-1871.
238. NA-BANGCHANG K, RUENGWEERAYUT R, KARBWANG J, CHAUEMUNG A, HUTCHINSON D: Pharmacokinetics and pharmacodynamics of fosmidomycin monotherapy and combination therapy with clindamycin in the treatment of multidrug resistant falciparum malaria. Malar. J. (2007) 6(1):70.
239. KAYE D: Death from malaria following inappropriate chemoprophylaxis. Clin. Infect. Dig. (2001) 33(5):1.
240. GARDNER MJ, HALL N, FUNG E et al.: Genome sequence of the human malaria parasite Plasmodium falciparum. Nature (2002) 419(6906):498-511.
241. FLORENS L, WASHBURN MP, RAINE JD et al.: A proteomic view of the Plasmodium falciparum life cycle. Nature (2002) 419(6906):520-526.
242. LASONDER E, ISHIHAMA Y, ANDERSEN JS et al.: Analysis of the Plasmodium falciparum proteome by high-accuracy mass spectrometry. Nature (2002) 419(6906):537-542.
243. BATHURST I, HENTSCHEL C: Medicines for malaria venture: sustaining antimalarial drug development. Trends Parasitol. (2006) 22(7):301-307.